FIELD: chemistry.
SUBSTANCE: invention relates to a co-crystalline form of bicalutamide with 2-hydroxybenzamide with molar ratio of 1:1. The co-crystalline form has: an endothermic peak from 156°C to 160°C based on measurement data through differential scanning calorimetry (DSC analysis), peaks at 2θ(°) 3.16, 4.94, 5.66, 26.1 based on measuring X-ray diffraction of the monocrystal.
EFFECT: obtaining a novel co-crystalline form of bicalutamide with a high rate and level of solubility, which can be used as a pharmaceutical preparation for treating prostate cancer.
5 cl, 7 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE AND 4-AMINOBENZOIC ACID | 2012 |
|
RU2497804C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE WITH SALICYLIC ACID | 2013 |
|
RU2539350C1 |
| COCRYSTALLINE FORM OF FENBUFEN | 2012 |
|
RU2521572C1 |
| COCRYSTALLINE FORM OF NIFLUMIC ACID WITH ISONICOTINAMIDE OT CAFFEINE | 2013 |
|
RU2536484C1 |
| CO-CRYSTALLINE FORM OF THEOPHYLLINE WITH DIFLUNISAL OR DICLOFENAC | 2013 |
|
RU2542100C1 |
| DIFLUNISAL CO-CRYSTALLINE FORM | 2016 |
|
RU2617849C1 |
| CO-CRYSTALLINE FORM OF ISONIAZID | 2016 |
|
RU2630957C1 |
| CO-CRYSTALLINE FORM OF 1-[(5-PARA-METHYL-META-CHLORO-PHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2019 |
|
RU2721335C1 |
| CO-CRYSTALLINE FORMS OF THEOPHYLLINE | 2022 |
|
RU2805752C2 |
| COCRYSTALLINE FORM OF 1-[5-(4-CHLOROPHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2018 |
|
RU2712443C1 |
